ARQT News and Press, Arcutis Biotherapeutics Inc. From 10/02/20

Shares of Arcutis Biotherapeutics (NASDAQ: ARQT) are down by 14.3% as of 12:12 p.m. EDT on Friday, after the company announced the pricing of a public offering of common stock. Investors typically react to stock offerings by selling off shares of the company in question, and it isn'...

Gainers: Aduro Biotech (ADRO) +442%, American Renal Associates (ARA) +69%, Nano-X Imaging (NNOX) +38%, CTI BioPharma (CTIC) +18%, ProPhase Labs (PRPH) +16%.Losers: Benitec Biopharma (BNTC) -36%, Mesoblast (MESO) -36%, Arcutis Biotherapeut...

Arcutis receives a boost with positive seborrheic dermatitis study data. Integra LifeSciences to divest extremity orthopedics business. Alnylam announces positive data from Phase Lumasiran. For further details see: Arcutis Announces Positive Data, And Other News: The Goo...

Arcutis Biotherapeutics (ARQT) has priced its public offering of 4M common shares at $25.00/share, for the expected gross proceeds of $100M.Underwriters' over-allotment is an additional 600K shares.Closing date is Oct. 6. Concurrently, Arcutis expects to sell to entities affiliated with OrbiM...

WESTLAKE VILLAGE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatol...

Arcutis Biotherapeutics (ARQT) announces underwritten public offering of 4M shares of its common stock. Underwriters overallotment option will be additional 600K shares.Price has yet to be determined.The company also plans concurrent $35M private placement of common stock to OrbiMed Advi...

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermato...

Arcutis Biotherapeutics ( ARQT -0.4% ) has completed enrollment in DERMIS-1 and DERMIS-2, the Company’s pivotal Phase 3 clinical trials evaluating ARQ-151 (topical roflumilast cream) as a potential topical treatment for plaque psoriasis . More news on: Arcutis Biotherapeuti...

Roflumilast cream potential “Best in Class” topical PDE4 inhibitor Plaque psoriasis affects approximately 8.6 million patients in the U.S. Phase 3 trials topline data now anticipated in the first quarter of 2021 and New Drug Application (NDA) submission anticipated by the ...

WESTLAKE VILLAGE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derma...